Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced nasopharyngeal cancer
2007-001530-14Phase 3Active
- Sponsor
- GORTEC
- Start
- Sep 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, cisplatin and fluorouracil in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by GORTEC. Primary endpoints: 3-year progression-free survival and objective response rate. Started Sep 2007; status: active.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on 2007-001530-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001530-14.